Nasus Pharma Ltd.
NSRX•NYSEAMERICAN•Healthcare•Drug Manufacturers - General

About Nasus Pharma

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.nasuspharma.com
Phone972 3 573 6632
Address
Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel

Corporate Identifiers

CIK0002029039
CUSIP001218155
ISINIL0012181553
EIN51-6022712
SIC2834

Leadership Team & Key Executives

Dan Teleman MBA M.Sc.
Chief Executive Officer and Director
Ehud Moshe Gilboa MBA
Co-Founder and Executive Chairman
Dr. Dalia Megiddo M.B.A., M.D., Ph.D.
Co-Founder, Chief Development Officer? and Director
Eyal Rubin M.B.A.
Chief Financial Officer and Senior Vice President
Dr. Galia Temtsin Kryaz Ph.D.
Director of CMC and Product Development